Using IPA rate to assess the high platelet reactivity of patient with coronary heart disease
10.3969/j.issn.1006-5725.2017.20.022
- VernacularTitle:血小板聚集抑制率评估冠心病行PCI术患者的血小板高反应性
- Author:
Jia LIU
1
;
Lianjun SHEN
;
Jing ZHANG
;
Shenghu HE
Author Information
1. 江苏省苏北人民医院药学部
- Keywords:
inhibition of platelet aggregation;
coronary heart disease;
high platelet reactivity;
PCI
- From:
The Journal of Practical Medicine
2017;33(20):3416-3419
- CountryChina
- Language:Chinese
-
Abstract:
Objective Using IPA rate to assess platelet reactivity of coronary heart disease patients re-ceived the dual antiplatelet therapy after PCI. Methods CHD patients received the loading dose of clopidogrel (300 mg)on the first day of hospitalization or before PCI,then received clopidogrel(75 mg/d)and aspirin(100 mg/d) for one year. IPA was measured after administration of the loading dose of clopidogrel. The patients were divided into the HPR and LPR group according to the rate of IPA. Observe patients incidences of cardiovascular events were followed up for one year. Results A total of 102 patients were enrolled into this study ,including 77 males and 25 females with average age of 65.7 ± 10.9. Patients were divided into the HPR and LPR group with 69 and 33 patients,respectively. The average IPA value of HPR group was obvious lower than that of LPR group(P<0.01). The accumulative 12-month cardiovascular events incidence in the HPR and LPR group were 15.9% and 3.0% respectively ,with significant difference (P < 0.05). Conclusion IPA could be used to evaluate platelet reactivity,which suggests that clinicians can detect IPA to reduce or avoid the recurrence of cardiovascular events.
